NEW YORK (GenomeWeb news) – Luminex reported after the close of the market on Wednesday that its third-quarter 2009 revenues rose nearly one percent, and it swung to a loss compared to a profit for the year-ago period.

The Austin, Texas-based molecular diagnostics instrumentation and assay maker had revenues of $29.1million for the three-month period ended Sept.30, compared to revenues of $28.9 million for the third quarter last year. Sales for its technology group fell to $22 million from $22.6 million, while sales for its assay group rose to $7.1 million from $6.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.